GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio

Lilly’s Omvoh shows rapid and lasting relief from bowel urgency in ulcerative colitis patients

Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US

Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs

FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes

This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms

MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain

Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation

AskBio’s gene therapy shows promising 12-month results for heart failure

Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure

FDA approves Alembic's Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients

Sai Life Sciences to double process R&D capacity with new facility in Hyderabad

The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization

Sanofi India appoints Deepak Arora as MD

Arora brings over 30 years of experience in the pharmaceutical and healthcare industry

Lilly buys Adverum for its phase 3-stage eye disease gene therapy

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose